All‐cause mortality · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
self‐management of oral anticoagulation probably leads to lower all‐cause mortality compared with standard care (moderate certainty).
1 finding from 1 review
All‐cause mortality · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring of oral anticoagulation showed no clear difference in all‐cause mortality compared with standard care (moderate certainty).
1 finding from 1 review
All‐cause mortality · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring or self‐management of oral anticoagulation showed no clear difference in all‐cause mortality compared with standard care (moderate certainty).
1 finding from 1 review
All‐cause mortality during hospital stay and all‐cause mortality at 1 year · people with endocarditis on the left side of the heart (on native or prosthetic valves) with bacteraemia for Streptococcus, Enterococcus…
It is very uncertain whether partial oral treatment changes all‐cause mortality during hospital stay and all‐cause mortality at… compared with conventional intravenous treatment of endocarditis on the left side… (very low certainty).
1 finding from 1 review
Short‐term all‐cause mortality · people with coronary artery disease undergoing diagnostic coronary angiography and percutaneous coronary intervention
Transradial leads to lower short‐term all‐cause mortality compared with transfemoral approach (high certainty).
1 finding from 1 review
All‐cause mortality · Human trial participants undergoing ablation for atrial fibrillation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · Human trial participants undergoing ablation for atrial fibrillation
It is very uncertain whether class III antiarrhythmics changes all‐cause mortality compared with control (very low certainty).
1 finding from 1 review
All‐cause mortality · Human trial participants undergoing ablation for atrial fibrillation
Class I and/or III antiarrhythmics showed no clear difference in all‐cause mortality compared with control (low certainty).
1 finding from 1 review